Company
Abbott Laboratories
Abbott Laboratories has 10 drugs tracked on RxWires: 2 post-market, 6 approved, 2 in Phase 3.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Atorvastatin | Post-Market | Coronary Artery Disease |
| Creon | Post-Market | Exocrine Pancreatic Insufficiency in Subjects With Diabetes Mellitus Type 2 |
| CALCIUM GLUCEPTATE | Approved | |
| A-METHAPRED | Approved | |
| GENTAMICIN SULFATE | Approved | |
| A-HYDROCORT | Approved | |
| ERYTHROCIN | Approved | |
| IBU | Approved | |
| PAL-40 Active | Phase 3 | End Stage Renal Disease |
| Ademetionine IV+tablet | Phase 3 | Intrahepatic Cholestasis Associated With Alcoholic Liver Disease |
Latest
- abbott laboratories filed 8-K
- abbott laboratories filed 8-K
- abbott laboratories filed 8-K
- abbott laboratories filed 8-K
- abbott laboratories filed 8-K
Follow Abbott Laboratories on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.